After over 50 years of use, lithium-salts remain the first-line therapy for the management of bipolar disorder. Throughout this period, the potential for lithium salts has been extensively studied and numerous data favor its use in the treatment of neurodegenerative disorders such as Alzheimer’s disease (AD). We reviewed existing evidence gathered from clinical case reports and studies on the effect of lithium on neuropsychological symptoms of AD and as a disease-modifying treatment acting on cognitive symptoms. The review summarizes the molecular pathways, involving GSK-3β inhibition and neuroprotection, through which lithium is proposed to exert its effect. Limitations to its current use in AD are discussed and future perspectives as a potential treatment option for AD are considered in regard to ongoing clinical trials using different forms of lithium.
BaastrupPC, PoulsenJC, SchouM, ThomsenK, AmdisenA (1970) Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet296, 326–330.
2.
CadeJF (2000) Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ78, 518–520.
3.
MarmolF (2008) Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry32, 1761–1771.
4.
FDA Highlights of prescribing information: LITHOBID®.
5.
CiprianiA, HawtonK, StocktonS, GeddesJR (2013) Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ346, f3646.
6.
ForlenzaOV, De-PaulaVJR, DinizBSO (2014) Neuroprotective effects of lithium: Implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders. ACS Chem Neurosci5, 443–450.
7.
DevanandDP, PeltonGH, D’AntonioK, StricklerJG, KreislWC, NobleJ, MarderK, SkomorowskyA, HueyED (2017) Low-dose lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: A case series. Alzheimer Dis Assoc Disord31, 73–75.
8.
DevanandDP, StricklerJG, HueyED, CroccoE, ForesterBP, HusainMM, VahiaIV, AndrewsH, WallMM, PeltonGH (2018) Lithium treatment for agitation in Alzheimer’s disease (Lit-AD): Clinical rationale and study design. Contemp Clin Trials71, 33–39.
KessingLV, SøndergårdL, FormanJL, AndersenPK (2008) Lithium treatment and risk of dementia. Arch Gen Psychiatry65, 1331–1335.
11.
KessingLV, FormanJL, AndersenPK (2010) Does lithium protect against dementia?Bipolar Disord12, 87–94.
12.
MacdonaldA, BriggsK, PoppeM, HigginsA, VelayudhanL, LovestoneS (2008) A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry23, 704–711.
ForlenzaOV, RadanovicM, TalibLL, GattazWF (2019) Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: Randomised clinical trial. Br J Psychiatry215, 668–674.
17.
DamianoRF, LoureiroJC, PaisMV, PereiraRF, Corradi deM M, SantiTD, BezerraGAM, RadanovicM, TalibLL, ForlenzaOV (2023) Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. Braz J Psychiatry45, 46–49.
18.
NunesMA, VielTA, BuckHS (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res10, 104–107.
19.
MauerS, VergneD, GhaemiSN (2014) Standard and trace-dose lithium: A systematic review of dementia prevention and other behavioral benefits. Aust N Z J Psychiatry48, 809–818.
20.
MatsunagaS, KishiT, AnnasP, BasunH, HampelH, IwataN (2015) Lithium as a treatment for Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis48, 403–410.
21.
Machado-VieiraR, ManjiHK, ZarateCA (2009) The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord11(Suppl 2), 92–109.
ChuangD-M (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases?Crit Rev Neurobiol16, 83–90.
28.
LazzaraCA, KimY-H (2015) Potential application of lithium in Parkinson’s and other neurodegenerative diseases. Front Neurosci9, 403.
29.
ShineB, McKnightRF, LeaverL, GeddesJR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: A retrospective analysis of laboratory data. Lancet386, 461–468.
AyanoG (2016) Bipolar disorders and lithium: Pharmacokinetics, pharmacodynamics, therapeutic effects and indications of lithium: Review of articles. Austin J Psychiatry Behav Sci3, 1053.
32.
TimmerRT, SandsJM (1999) DISEASE OF THE MONTH: Lithium intoxication. J Am Soc Nephrol10, 666–674.
33.
KakhkiS, Ahmadi-SoleimaniSM (2022) Experimental data on lithium salts: From neuroprotection to multi-organ complications. Life Sci306, 120811.
34.
Medesis PharmaSA (2023) Prospective, Multicenter, First Part Randomized, Placebo-controlled, Parallel-group, Double-blind Period Followed by Open-label Trial Period to Evaluate Clinical Safety & Efficacy of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer’s Disease: Proof-of-concept Study, clinicaltrials.gov.
35.
MouriA, DiatO, El GhzaouiA, BauerC, MaurelJC, DevoisselleJ-M, DorandeuC, LegrandP (2014) Phase behavior of reverse microemulsions based on Peceol(®). J Colloid Interface Sci416, 139–146.
36.
MouriA, DiatO, El GhzaouiA, LyI, DorandeuC, MaurelJC, DevoisselleJ-M, LegrandP (2015) Development of pharmaceutical clear gel based on Peceol®, lecithin, ethanol and water: Physicochemical characterization and stability study. J Colloid Interface Sci457, 152–161.
37.
MouriA, DiatO, LernerDA, El GhzaouiA, AjovalasitA, DorandeuC, MaurelJ-C, DevoisselleJ-M, LegrandP (2014) Water solubilization capacity of pharmaceutical microemulsions based on Peceol®, lecithin and ethanol. Int J Pharm475, 324–334.
38.
MouriA, LegrandP, El GhzaouiA, DorandeuC, MaurelJC, DevoisselleJ-M (2016) Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system. Int J Pharm502, 117–124.
39.
SaddarS, CarriereV, LeeW-R, TanigakiK, YuhannaIS, ParathathS, MorelE, WarrierM, SawyerJK, GerardRD, TemelRE, BrownJM, ConnellyM, MineoC, ShaulPW (2013) Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res112, 140–151.
40.
WilsonEN, Do CarmoS, IulitaMF, HallH, DucatenzeilerA, MarksAR, AllardS, JiaDT, WindheimJ, CuelloAC (2017) BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Transl Psychiatry7, e1190.
41.
WilsonEN, Do CarmoS, WelikovitchLA, HallH, AguilarLF, ForetMK, IulitaMF, JiaDT, MarksAR, AllardS, EmmersonJT, DucatenzeilerA, CuelloAC (2020) NP03, a microdose lithium formulation, blunts early amyloid post-plaque neuropathology in McGill-R-Thy1-APP Alzheimer-like transgenic rats. J Alzheimers Dis73, 723–739.
42.
WilsonEN, Do CarmoS, IulitaMF, HallH, AustinGL, JiaDT, MalcolmJC, ForetMK, MarksAR, ButterfieldDA, CuelloAC (2018) Microdose lithium NP03 diminishes pre-plaque oxidative damage and neuroinflammation in a rat model of Alzheimer’s-like amyloidosis. Curr Alzheimer Res15, 1220–1230.
43.
SotoM, GuiliotS, OussetPJ, AngioniD, Hengan SastreN, MaurelJC, TouchonJ (2022) A proof-of-concept study to evaluate efficacy of nanolithium on the progression of neuropsychiatric symptoms in patients with mild-to-severe Alzheimer’s disease. J Prev Alzheimers Dis9(Suppl 1), S207–S208.
44.
Alzamend Neuro, Inc. (2023) A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients with Mild to Moderate Alzheimer’s Disease and Healthy Adult Subjects (“MAD Study”), clinicaltrials.gov.
45.
HabibA, ShytleRD, SawmillerD, KoilrajS, MunnaSA, RongoD, HouH, BorlonganCV, CurrierG, TanJ (2019) Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer’s mice. J Neurosci Res97, 1066–1080.
CreeseB, IsmailZ (2022) Mild behavioral impairment: Measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease. Alzheimers Res Ther14, 2.
49.
AvramopoulosD, KapogiannisD, LeoutsakosJ-M, LyketsosCG, MahairakiV, NowrangiM, OishiK, OhES, RosenbergPB, SamusQ, SmithGS, WitwerK, YasarS, ZandiPP (2021) Developing treatments for Alzheimer’s and related disorders with precision medicine: A vision. Adv Exp Med Biol1339, 395–402.
50.
van DyckCH, SwansonCJ, AisenP, BatemanRJ, ChenC, GeeM, KanekiyoM, LiD, ReydermanL, CohenS, FroelichL, KatayamaS, SabbaghM, VellasB, WatsonD, DhaddaS, IrizarryM, KramerLD, IwatsuboT (2023) Lecanemab in early Alzheimer’s dfisease. N Engl J Med388, 9–21.
51.
Washington University School of Medicine (2023) A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease, clinicaltrials.gov.
